{"name":"CKD Bio Corporation","slug":"ckd-bio-corporation","ticker":"","exchange":"","domain":"ckdbiocorporation.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Botox®50U","genericName":"Botox®50U","slug":"botox50u","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CKDB-501A","genericName":"CKDB-501A","slug":"ckdb-501a","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Botox®50U","genericName":"Botox®50U","slug":"botox50u","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKDB-501A","genericName":"CKDB-501A","slug":"ckdb-501a","phase":"phase_3","mechanism":"CKDB-501A is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQTl9DNVZsaUp3dW9qYXllZTJ1eTVyRDJERXFlUy1jM3JjMFAyOWlLM3VVc09zbjU2SlJkdXd3d18zMWZhZThnZVFSdkI2dV94UjlVRHFpQmZMbDYwbmFZakRiZFhVWEh4VTJtYVV4X3dSYk5EY2RpUGlObmRvMWRWWHBCd0k2WHpYc1E?oc=5","date":"2026-04-07","type":"pipeline","source":"NutraIngredients.com","summary":"CKD Bio on respiratory health: Underdeveloped but holds significant growth potential - NutraIngredients.com","headline":"CKD Bio on respiratory health: Underdeveloped but holds significant growth potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOU212bjktRDk0bnhIdE94TUg5VlVLaFQ0dkctOFk2RTROVzhRZExPMDZQVUkwQUdKaTRvdUVlTjJmUDFpTkdtWnNNQ3o3QnI5TDI3bExTdmNYQlB3UklIRzJkTUJiLWdERUtaSEFIenNTYnZpMlFPSTRycVRzRERyQTlqaEpXc1RKQ1ZVUHlpaVJENERnbXc?oc=5","date":"2026-03-30","type":"deal","source":"Seoul Economic Daily","summary":"Korean Pharma Firms Acquire VCs to Drive Drug and Healthcare Investments - Seoul Economic Daily","headline":"Korean Pharma Firms Acquire VCs to Drive Drug and Healthcare Investments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNd0h1ZWI1X3ZPa3pxSVlPUkctRFF1NklObkRDSkdoYzlQZy0wVGwwRVBveTM4UkVnT0NGUlNuZmg3dkR1cFpaeFpQWkNsdldtRnh4OWdLWW9jNUcxbDRrQkNnVUZmMHJWNU5WMENubUZocTEyeElIMGs0MG5BUHZjNmpWXzEwdGVySVZsNWF1XzNwZndJTUNoWTNXemJHMkU?oc=5","date":"2026-03-29","type":"deal","source":"Seoul Economic Daily","summary":"Korean Pharma Firms Acquire VCs to Invest Directly in Drugs, Cosmetics, Medical Devices - Seoul Economic Daily","headline":"Korean Pharma Firms Acquire VCs to Invest Directly in Drugs, Cosmetics, Medical Devices","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTFBIMGR0RUR1OS12TkJzX2YxQnd4Q1lYVi0yM3JtUkxOYklEeElxbm9WNTlPNGlxTmJOX1hSNk9jWUNqdHExNVpXYlhWSQ?oc=5","date":"2026-03-24","type":"pipeline","source":"매일경제","summary":"Chong Kun Dang is speeding up its transformation into a \"global bio company\" that leads the developm.. - 매일경제","headline":"Chong Kun Dang is speeding up its transformation into a \"global bio company\" that leads the developm.. - 매일경제","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQdDJWRGdBRmotQWRmYk5Fb1RkZHBuUzFiQ2tpam9GOUxncW55cFNmN2pjbXprQ0pWNEZKZTdsWnV3ZDRVMHZMZVcxSW1jX1VzWTB3eHpPSHRKLVV3Z05uYl9FZjNLZUNVTVI5ZVhNLXREUnVCYl9FeXQ3a2dWOTE2dTJNanlXUGdzUi1MZ1FnYjNiQlhWMGdmbm10RkRBV2VTZERZb25vLVRMZ1dNd3lF?oc=5","date":"2026-01-06","type":"deal","source":"Fierce Biotech","summary":"Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact - Fierce Biotech","headline":"Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQQkpEUE95bS1wd0lxN0gtWjF1eGdpUDBUTDJYNmw5ODA0Q2NXTjdDbUJMVHdqOUdjenRJVGQxWXYtTUNkQVBKaDJQOEtjQkVvZDVqOFZPckxpN0t2elFFY0FkRmJ4M1E5Mkt0UjRnV2ZjT3VzRGhkTFlGQ2VJVFkxd1VFSnFxYm4wa0JiTDhyT01YVE51TVlRelJ3bzVsWThKZ2h2Ykc3Y2Vta0VPaEFOZVlfSUhzTmNFTjVVVlRhaERucy1DU0hXcFNmcw?oc=5","date":"2025-12-22","type":"deal","source":"Contract Pharma","summary":"Rectify Pharmaceuticals, Boehringer Ingelheim Partner to Accelerate Treatments for CKD - Contract Pharma","headline":"Rectify Pharmaceuticals, Boehringer Ingelheim Partner to Accelerate Treatments for CKD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeG9WX09ZU000MUV2U2JtSmRjenpRd1N6RmNZQTNtU1l0cnFJS28xWVJOdVJ2S3BVcnlUNXBGTkxUM0FEN1E5NHRYX1VYWkRfcVZmZ0dwcWtWX2xpa0p5R0F1WXlSdUNiUXZrekFpWktiZFZsX2drY0JsMjFtdlRwMGJVdmRhbkhoN3ByWjFhVl9ZS1ZNanV6UkdzQ0dqUzJCR0wzTHE3enY?oc=5","date":"2025-07-29","type":"pipeline","source":"BioWorld News","summary":"South Korea hits record $23B pharma production; 2024 exports up 28% - BioWorld News","headline":"South Korea hits record $23B pharma production; 2024 exports up 28%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPN3dKLWxIa29uUkhHalBDdnBZWDZjbjdRLWZzX0RwMjBNYm1oa2YtSXNwczk4dGNpdGVmbEVKdUxRN3gwOXBtNUJnRDNUa3lsR1F0bElLQ0VhbXNnaXdMMVNkdmlDamhndV8wUU9oUi1iUzAtWjV6WVZrcHVzRFVCWlJSd0R2MXh1cU5ZTy1fYTJ1WV9zWC0wNGJkQUFRdHlkbWtRQjNxU1BsWlpMbHFSaGFEVVAtX1JzaFVpSEJBdmVIWjNzaWFkZjR3?oc=5","date":"2025-07-16","type":"pipeline","source":"Inside Precision Medicine","summary":"Cyst-ine Chapel: Renasant Bio Launches to Solve Complex Kidney Disease ADPKD - Inside Precision Medicine","headline":"Cyst-ine Chapel: Renasant Bio Launches to Solve Complex Kidney Disease ADPKD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNRTAyWG5uelZ1TlA1TVpPeVJ6WTlfbkJqYW9Ydk80Z1ZpdEhHYVlxREt2bmdSWEo5MWhEeFpTV01EUnBtVUo3R3MtOVRJN1lQcHlqUlN3YWRLcUx5OHhBV2M3VWNEWUFlWTBhVGNlZ01jZkM3ZGJoWVVEX0I2ekpvWdIBlAFBVV95cUxOMV8zVTVDSDNiVW11dElXd3RQSnlXNXYzUmYwTnNHMmMyZ0hiMTJxVWpQckFSZExCTzBYb3BaQkg1bVV0Zl9yWThhQ1ZxTE9zTmoyZGR3NzNiR2VsSXNzdjhSNkt6c3hsMERRcUE2QWt0dWxmN2Y3anY0ckwtTUNabHJubnhrM2lhMVJyTEU0OXVnamdn?oc=5","date":"2025-07-02","type":"pipeline","source":"Chosunbiz","summary":"Chong Kun Dang leads global drug development with innovative biotechnologies - CHOSUNBIZ - Chosunbiz","headline":"Chong Kun Dang leads global drug development with innovative biotechnologies - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFA3clliS21GWnJMczZpQUg0QWQxdkYxd1UyNW5fcTZGU0FEWUMwLXlQRndaUVZDcEtoX1BKVlhtX3lSWjV1OHJmSlBLRTFBXzZueE1GTUdreXcyX3Raa1dMbTVFbW5mclNaRHFJdk5Fd2c?oc=5","date":"2025-06-23","type":"pipeline","source":"Labiotech.eu","summary":"Six kidney disease companies you should know about in 2025 - Labiotech.eu","headline":"Six kidney disease companies you should know about in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5WTXN1OHl4U3VFOGxJUzk1Yk9FLVFhTjA4Smxrc1oyVFZ6aVdMOHhEZFhrTjlqNjQ3WldtZjg4ZGJlaGJuMmV5SjVyanBrTW8xUVlVdEdrLXRiNHdySjA4YXBGQU94TGpaRTI4aE130gFyQVVfeXFMUDZuRFp4SWNiYkN3eHNGb01ORHB1WElvRUdVdF9VN016TjhiUTFEbjFOV1ZVR1ZuNUZhcllNWWJUVjVTQ3pEdVh2SzFIYUhRZlJvc2lVWEpFYlpPNDMtVEd4YlhVTGFJN01tZXVhbktXNHZn?oc=5","date":"2025-04-01","type":"pipeline","source":"koreabiomed.com","summary":"CKD Bio’s BTX product wins nod to advance to global markets - koreabiomed.com","headline":"CKD Bio’s BTX product wins nod to advance to global markets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPbHAweGdhM3Vva0tMRU9IXzdqZ25wSU1ZNXliNjBNc1Fsbk1IaUZLRWRZSnlTMzZ6cFhPRTJZU01HYXV3TkF1b1p6eldhMXJwNGllUVppTXgzNVkyYzlmbUZrQkFHRnRLSXlnUENYUFpacVVYNjU0NHM3QXNxTlNlaEE1QlhoalVBVGFKQjdNRHlGWnVHNkxhRUZ1T3JQSHBvWElB?oc=5","date":"2023-11-07","type":"pipeline","source":"BioSpace","summary":"Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule - BioSpace","headline":"Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}